Everything below concerns freeze-thaw cycle. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-27. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
The saboteur is eventually revealed to be a bird pecking at the console's keyboard, which sends GLaDOS into a panic when she recognizes it as the one who tried to eat her during her time as a potato. ATLAS and P-body manage to shoo away the bird, earning a rare compliment from GLaDOS before she notices eggs in its nest. Instead of having them smashed, GLaDOS has the eggs taken to her chamber so that she can raise the baby birds to be her own little "killing machines". According to GLaDOS, ATLAS and P-body were created for the Cooperative Testing Initiative and were supposed to phase out human testing after Chell escaped with Wheatley. However, she never got around to using them for testing. In the Portal 2 singleplayer campaign, Wheatley finds both ATLAS and P-body in storage and decided to kill both Chell and GLaDOS and use them instead. They later appear when Chell is granted liberty by GLaDOS. Originally, the co-op player characters would be Chell (the single player character), and Mel, another human test subject. This concept was cut when playtesting showed that co-op characters would die a lot. The humans were replaced with infinite respawning robots. During the early phases of Portal 2, ATLAS and P-body's concept showed more of a Westworld feel.
Insulin detemir is a long-acting modified form of medical insulin used to treat both type 1 and type 2 diabetes. It is administered through subcutaneous injection. Its effects last for up to 24 hours. Common side effects include (hypoglycemia, allergic reactions, pain at the injection site, and weight gain. It appears to be safe for use during pregnancy and breastfeeding. Insulin detemir works by increasing the amount of glucose absorbed by tissues and reducing the amount of glucose produced by the liver. Insulin detemir was approved for medical use in the European Union in June 2004 and in the United States in June 2005. It is listed on the World Health Organization's List of Essential Medicines. In 2022, it was the 127th most commonly prescribed medication in the United States, with over 4 million prescriptions. Insulin detemir is only sold under the name Levemir by Novo Nordisk, who owned its patent until 2019. in certain countries, Levemir and certain related products were discontinued in 2024.
The public's lack of understanding regarding nicotine's biological effects frequently results in inaccurate claims disseminated by the media and general public. In some anti-smoking literature, the harm that tobacco smoking and nicotine addiction does is personified as Nick O'Teen, represented as a humanoid with some aspect of a cigarette or cigarette butt about him or his clothes and hat. Nick O'Teen was a villain that was created for the Health Education Council. The character was featured in three animated anti-smoking public service announcements in which he tries to get kids addicted to cigarettes before being foiled by the DC Comics character Superman. Nicotine was often compared to caffeine in advertisements in the 1980s by the tobacco industry, and later in the 2010s by the electronic cigarettes industry, in an effort to reduce the stigmatization and the public perception of the risks associated with nicotine use.
Dermal macrophages are primarily populated in the dermis of the skin as they are specialised in skin homeostasis and repair. There are three inter-linked stages in skin wound healing: inflammation, tissue formation, and maturation. Dermal macrophages serve the function of bridging the three stages of wound healing. The first stage occurs from day 0 to 5 post-injury. This stage is an inflammatory response induced by dermal macrophages to initiate the tissue repairing process. Similar to their functions in innate immunity, dermal macrophages stimulate an inflammatory response during the first stage of wound repair by releasing pro-inflammatory factors. This allows infiltration of immune cells and factors facilitating tissue regeneration. Dermal macrophages are associated with the production of proliferation factors such as TGFβ1 and VEGF-A. The factors are produced to initiate the second stage, tissue formation. Tissue formation occurs from day 5 to 10 post-injury. In this stage, dermal macrophages' primary role is to generate a primary structure for wound repairing via granulation and collagen deposition. They also mediate re-epithelialisation and neo-angiogenesis by producing TGFβ1 and VEGF-A, as in the inflammation stage. Dermal macrophages are essential in the transition between the second and third stages. Deficiency in dermal macrophages might induce unfavourable morphological changes in the wound because of compromised removal of tissue debris via phagocytosis. Dermal macrophages mediate the final stage of tissue maturation and wound remodelling.
Sources: en.wikipedia.org
18 January The ONS reports that inflation dropped for the second month running, to 10.5% in December, from 10.7% the previous month. At the two extremes of the ONS's list of "notable movements" that contribute to the overall figure, 'clothing and footwear' price inflation dropped from 7.5% to 6.4%, 'furniture and household goods' dropped from 10.8% to 9.8%, 'food and non-alcoholic beverages' rose from 16.5% to 16.9%, and 'restaurants and hotels' rose from 10.2% to 11.4%. BBC News reports that Church of England bishops will not give their backing to a change in teaching that would allow them to marry same-sex couples, but the Church will offer "prayers of dedication, thanksgiving or God's blessing" to gay couples. 19 January – Prime Minister Rishi Sunak apologises for taking his seat belt off in a moving car to film a social media clip. Lancashire Police later say they are "looking into" the incident. He is issued with a fixed-penalty notice the following day. 20 January The Church of England issues an apology for the "shameful" times it has "rejected or excluded" LGBTQ+ people, while Archbishop of Canterbury Justin Welby says he supports the changes that allow blessings to be offered to gay couples, but says he will not personally use them because he has a "responsibility to the whole communion". The High Court awards £39m in damages against Frimley Health NHS Foundation Trust in Surrey to a girl whose limbs were amputated after she was wrongly diagnosed.
After the lipids are separated on the GC or LC column they are detected using mass spectrometry (MS). Mass spectrometry characterizes the mass of a given molecule by first fragmenting and ionizing the molecule into smaller carbocations known as daughter ions. Each molecule has a diagnostic fragmentation pattern in a given ion source. Classes of molecules often have a characteristic fragment ion that can be used to search for those molecules in a total ion current. This is known as a selected ion chromatogram (SIC). SICs are used in single quadrupole mass spectrometers. When two quadrupoles are attached in tandem mass spectrometry (MS/MS), two mass fragments can be isolated simultaneously. MS/MS experiments allow the total ion current to be filtered by both the molecular ion and the characteristic fragment ion of a given molecule. The molecular ion of gammacerane with an electron impact source is 412 m/z. Like other pentacyclic triterpenoids, it has a characteristic 191 m/z mass fragment. The combination of 412 m/z and 191 m/z is known as the 412-->191 m/z transition and can be used to search a chromatogram specifically for gammacerane.
HGPS is caused by mutations that weaken the structure of the cell nucleus, making normal cell division difficult. The histone mark H4K20me3 is involved and caused by de novo mutations that occur in a gene that encodes lamin A. Lamin A is made but is not processed properly. This poor processing creates an abnormal nuclear morphology and disorganized heterochromatin. Patients also do not have appropriate DNA repair, and they also have increased genomic instability. In normal conditions, the LMNA gene codes for a structural protein called prelamin A, which undergoes a series of processing steps before attaining its final form, called lamin A. Prelamin A contains a "CAAX" where C is a cysteine, A an aliphatic amino acid, and X any amino acid. This motif at the carboxyl-termini of proteins triggers three sequential enzymatic modifications. First, protein farnesyltransferase catalyzes the addition of a farnesyl moiety to the cysteine. Second, an endoprotease that recognizes the farnesylated protein catalyzes the peptide bond's cleavage between the cysteine and -aaX. In the third step, isoprenylcysteine carboxyl methyltransferase catalyzes methylation of the carboxyl-terminal farnesyl cysteine. The farnesylated and methylated protein is transported through a nuclear pore to the interior of the nucleus. Once in the nucleus, the protein is cleaved by a protease called zinc metallopeptidase STE24 (ZMPSTE24), which removes the last 15 amino acids, which includes the farnesylated cysteine. After cleavage by the protease, prelamin A is referred to as lamin A.
=== Heart failure === In heart failure patients, angiotensin receptor blockers such as candesartan and valsartan may be a suitable option for those who do not tolerate angiotensin-converting enzyme inhibitor medicines. Randomised control trials have shown candesartan reduces heart failure hospitalisations and cardiovascular deaths for patients who have heart failure with reduced left ventricular ejection fraction (LVEF ≤ 40%).
=== Structural and sequence motifs === The structural and sequence motifs refer to short segments of protein three-dimensional structure or amino acid sequence that were found in a large number of different proteins
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.